艾美捷科技特约代理Exalpha公司产品。Exalpha位于美国迈阿密，成立20余年来，坚持以切实解决客户需求为导向，提供高品质的产品。

Exalpha was founded over 20 years ago by a group of scientists dedicated to accelerating the pace of discovery in the life science arena by rapidly developing and marketing unique products at the forefront of science.

In order to develop great products, you have to ask the right questions when you start. Where some companies are satisfied with ‘average’, ‘good enough’ or ‘me too’ products, Exalpha only settles for products that answer the pertinent questions. Exalpha continually monitors scientific trends and recent literature, we strive to produce products that answer real needs.  Exalpha has a long history of developing uniquely superior products that simply perform well, allowing researchers to focus on the task at hand and not on the quality of a supplier’s products.

产品主要包括：

Buffers and Reagents

Control Antibodies

Control Lysates

Kits

Proteins and Peptides

Primary Antibodies

Secondary Antibodies

Serum

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

Mediomics公司2001年成立，致力于为学术机构、制药公司、医学研究者、环境研究者提供创新性的检测试剂盒及生物感应物质。Mediomics拥有Patented Bridge-It® Assay Platform、Patented FRET-PINCER® Assay Platform、Patented TRF-PINCER® Assay Platform三大技术平台。

Mediomics, LLC provides innovative assay kits and biosensors needed by academic research laboratories, point of care testing, pharmaceutical companies, as well as medical and environmental research markets.  

Technology platforms:

（1）Patented Bridge-It® Assay Platform

Bridge-It® Assays are optimized to measure DNA binding proteins, their ligands, and co-regulators. Mediomics’ Bridge-It® assay was based on a simple idea of splitting the DNA binding site for a protein into two DNA half-sites. The presence of the DNA-binding protein or one of its ligands can be detected by FRET (fluorescence resonance energy transfer).

（2）Patented FRET-PINCER® Assay Platform

FRET-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. The patent-protected FRET-PINCER® Assay system detects the concentration of the target molecule by bringing together complementary single-stranded DNAs and their attached fluorophores to produce fluorescent light through FRET (fluorescence resonance energy transfer).

（3）Patented TRF-PINCER® Assay Platform

TRF-PINCER® Assays are a unique system to quantify the concentration of biomarkers, cells, and pathogens in a broad range of biological samples. The patent-protected TRF-PINCER® Assay platform system detects the concentration of the target molecule by bringing together complementary single-stranded DNAs and their attached fluorophores to produce fluorescent light with Time-Resolved Fluorometry (TRF) sensitivity.

主要产品线包括：

（1）Bridge-It® Assay

（2）TR-FRET Bridge-It® Assay

（3）FRET-PINCER® Assay

（4）TR-FRET PINCER®Assay

（5）Other

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

艾美捷科技特约代理Avidity Biosciences公司产品。

Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

Antibody oligonucleotide conjugate (AOC™) technology

Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.